Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

New additions to the Adis Journal Club – May update

Browse May's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

News

Adding BTK inhibitor to upadacitinib offers no benefit in RA

Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.

Hub

JAK inhibitor safety

Weigh up the safety data with summaries and expert discussion on the potential risks associated with JAK inhibitors.

Rituximab use in the COVID-19 era: striking the right balance

With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases (13:17).

COVID-19: Lessons learned for rheumatology practice

Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | COVID-19 & rheumatic disease

08-03-2022 | COVID-19 | News

Temporary methotrexate withdrawal may improve COVID-19 vaccine immunogenicity

Findings from the CoronavRheum trial suggest that suspension of methotrexate for 2 weeks after each dose of the Sinovac inactivated SARS-CoV-2 vaccine may improve antibody response rates to vaccination among people with rheumatoid arthritis.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

IN FOCUS | Inflammatory arthritis

29-04-2022 | Psoriatic arthritis | News

IL-22 levels may guide PsA treatment selection

Measuring IL-22 levels may help predict whether IL-17 inhibitors or TNF inhibitors are more suitable for patients with psoriatic arthritis, Japanese research suggests.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

IN FOCUS | Gout and crystal arthropathies

25-01-2022 | Gout | News

​​​​​​​Allopurinol use not linked to increased mortality risk in people with gout, CKD

Individuals with gout and concurrent chronic kidney disease are no more likely to die following allopurinol initiation, dose escalation, or achievement of target serum urate levels than those not taking the drug, study findings indicate.

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

IN FOCUS | JAK inhibitors

06-05-2022 | Rheumatoid arthritis | News

Adding BTK inhibitor to upadacitinib offers no benefit in RA

Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

IN FOCUS | Lupus

25-04-2022 | BSR 2022 | Conference coverage | News

Ancestry-specific gene expression profiles could help guide rituximab use in people with SLE

Gene expression profiles are associated with rituximab response among people of African or Asian ancestry with systemic lupus erythematosus, but not in those of European ancestry, research suggests.

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Podcasts

Interviews with expert rheumatologists on patient care